Drs Michael J. Mauro and Jane F. Apperley answer key questions about pregnancy and family planning for patients diagnosed with chronic myeloid leukemia, including complications and treatment options.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989029). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Managing Women of Childbearing Age With Chronic Myeloid Leukemia: Safety and Treatment Considerations https://pubmed.ncbi.nlm.nih.gov/37038615/

New Challenges in Human in Vitro Fertilization https://pubmed.ncbi.nlm.nih.gov/8493531/

Treatment of CML in Pregnancy https://pubmed.ncbi.nlm.nih.gov/36485083/

Outcome of Pregnancy in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors: Short Report From a Single Centre https://pubmed.ncbi.nlm.nih.gov/25455655/

Treatment-Free Remission: the New Goal in CML Therapy https://pubmed.ncbi.nlm.nih.gov/34618317/

The Effects of Imatinib on Pregnancy Outcome https://pubmed.ncbi.nlm.nih.gov/18322153/

Stage Specific Requirement of Platelet-Derived Growth Factor Receptor-Α in Embryonic Development https://pubmed.ncbi.nlm.nih.gov/28934221/

Drs Michael J. Mauro and Jerald P. Radich discuss monitoring and diagnostics in chronic myeloid leukemia, including the Philadelphia chromosome and how it plays into the current treatment of CML.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989028). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Chronic Myelogenous Leukemia (CML) https://emedicine.medscape.com/article/199425-overview

Genetics, Philadelphia Chromosome https://www.ncbi.nlm.nih.gov/books/NBK560689/

Reverse Transcriptase-Polymerase Chain Reaction https://emedicine.medscape.com/article/2093395-overview

Why Is It Critical to Achieve a Deep Molecular Response in Chronic Myeloid Leukemia? https://pubmed.ncbi.nlm.nih.gov/33054104/

Precision Oncology: Who, How, What, When, and When Not? https://ascopubs.org/doi/full/10.1200/EDBK_174176

Discovery of the Philadelphia Chromosome: A Personal Perspective https://pubmed.ncbi.nlm.nih.gov/17671636/

Dr. Janet Davison Rowley https://cfmedicine.nlm.nih.gov/physicians/biography_282.html

Metaphase https://www.genome.gov/genetics-glossary/Metaphase

A Primer on Genetic Testing https://www.medscape.com/viewarticle/505220_7

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors https://pubmed.ncbi.nlm.nih.gov/31612694/

Flow Cytometry: An Overview https://pubmed.ncbi.nlm.nih.gov/29512141/

Accelerated Phase Chronic Myelogenous Leukemia https://www.cancer.gov/publications/dictionaries/cancer-terms/def/accelerated-phase-chronic-myelogenous-leukemia

Treatment-Free Remission in CML: Who, How, and Why? https://pubmed.ncbi.nlm.nih.gov/29222243/

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/33283168/

Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/

t(14;18) Translocations and Risk of Follicular Lymphoma https://pubmed.ncbi.nlm.nih.gov/18648003/

CHIP https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/chip

The Max Foundation https://themaxfoundation.org/

BCR-ABL Fusion Gene https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bcr-abl-fusion-gene

Drs Michael J. Mauro and Michael W. Deininger discuss the evolution of chronic myeloid leukemia, better access to treatment, improved global cure rates, and a clearer definition of the word cure.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/11287972/

A Phase 2 Study of Imatinib in Patients With Relapsed or Refractory Philadelphia Chromosome-positive Acute Lymphoid Leukemias https://pubmed.ncbi.nlm.nih.gov/12200353/

International CML Foundation https://www.cml-foundation.org/

Resistance to Imatinib: Mechanisms and Management https://pubmed.ncbi.nlm.nih.gov/16316612/

Ponatinib Dose-ranging Study in Chronic-phase Chronic Myeloid Leukemia: A Randomized, Open-label Phase 2 Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34407543/

Asciminib Monotherapy in Patients With CML-CP Without BCR::ABL1 T315I Mutations Treated With at Least Two Prior TKIs: 4-year Phase 1 Safety and Efficacy Results https://pubmed.ncbi.nlm.nih.gov/36949155/

Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib https://pubmed.ncbi.nlm.nih.gov/32470534/

A Kinase Inhibitor Which Specifically Targets the ABL Myristate Pocket (STAMP), but Unlike Asciminib Crosses the Blood-brain Barrier https://pubmed.ncbi.nlm.nih.gov/35065232/

Olverembatinib (HQP1351), a Well-tolerated and Effective Tyrosine Kinase Inhibitor for Patients With T315I-mutated Chronic Myeloid Leukemia: Results of an Open-label, Multicenter Phase 1/2 Trial https://pubmed.ncbi.nlm.nih.gov/35982483/